On November 8th, 2023, the National Medical Product Administration (NMPA) of China made an announcement that Inaticabtagene Autoleucel had been approved for the treatment of
Carteyva (Relmacabtagene Autoleucel Injection), an anti-CD19 autologous chimeric antigen receptor T (CAR-T) cell immunotherapy product has been approved for the treatment of adult patients with
According to the latest reports, there are nearly 200 hospitals in China providing CAR T-cell therapy for the treatment of lymphoma.
The China National Medical Products Administration (NMPA) has agreed to review an application for Equecabtagene autoleucel — the country’s first chimeric antigen receptor (CAR) T-cell
Bristol Myers Squibb’s CAR-T drug Breyanzi has a sister med on the market.
The novel CAR T-cell therapy – Yescarta from Fosun Kite has recently been approved by the National Medical Products Administration (NMPA) in China.